Skip to main content

TransMedics Group, Inc.

For the period ended Mar 31, 2026. Filed May 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

TMDX$90.95-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(In thousands)

Three Months Ended March 31,
20262025
Cash flows from operating activities:
Net income$7,315$25,682
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization expense11,8646,137
Stock-based compensation expense9,9528,958
Deferred taxes1,067—
Non-cash interest expense4,593787
Non-cash operating lease expense610474
Unrealized foreign currency transaction (gains) losses486(573)
Loss on disposal of fixed assets—80
Changes in operating assets and liabilities:
Accounts receivable(6,520)(44,134)
Inventory(3,896)2,003
Prepaid expenses and other current assets1,9611,928
Other non-current assets(155)—
Accounts payable1,126781
Accrued expenses and other current liabilities(3,105)(4,644)
Deferred revenue40330
Operating lease liabilities(805)(664)
Net cash provided by (used in) operating activities24,533(2,855)
Cash flows from investing activities:
Purchases of property, plant and equipment(36,657)(27,038)
Net cash used in investing activities(36,657)(27,038)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options2,2121,742
Proceeds from issuance of common stock in connection with employee stock purchase plan1,6881,286
Tax withholding payments related to net settlement of restricted stock units(138)—
Net cash provided by financing activities3,7623,028
Effect of exchange rate changes on cash and restricted cash(327)358
Net decrease in cash and restricted cash(8,689)(26,507)
Cash and restricted cash, beginning of period488,866337,150
Cash and restricted cash, end of period$480,177$310,643
Supplemental disclosure of non-cash activities:
Transfers of inventory to property, plant and equipment$2,831$1,275
Purchases of property, plant and equipment included in accounts payable and accrued expenses$1,102$1,136
Operating lease liabilities arising from obtaining right-of-use assets$313$—
Finance lease liability arising from obtaining right-of-use assets$340,040$—
Purchases of property, plant and equipment included in other long-term liabilities$3,986$—
Reconciliation of cash and restricted cash:
Cash$461,739$310,143
Restricted cash18,438500
Total cash and restricted cash shown in the statement of cash flows$480,177$310,643
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.